Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

References

• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081–1088.
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Billie Bian C, Hoshida Y, et al. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99–105.
   PubMed Web of Science ®Google Scholar
• Incorporated VP. INCIVEK TM (Telaprevir) film coated tablets US prescribing information. Cambridge: Vertex Pharmaceuticals Incorporated; 2013.
   Google Scholar
• Merck Co Inc. VICTRELIS® (boceprevir) capsules for oral use. U.S prescribing information. Whitehouse Station; 2013 September.
   Google Scholar
• González-Grande R, Jiménez-Pérez M, González-Arjona C, et al. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22:1421–1432.
   PubMed Web of Science ®Google Scholar
• Gilead Science. Sovaldi® (Sofosbuvir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Janssen-Cilag. OLYSIO ® (Simeprevir) capsules, for oral use. Full prescribing information; 2017Dec.
   Google Scholar
• Bristol-Myers Squibb Company. DAKLINZA TM (Daclatasvir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Gilead Sciences. HARVONI® (Ledipasvir and Sofosbuvir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• AbbVie Ltd. VIEKIRA PAK (Ombitasvir, Paritaprevir, and ritonavir tablets; Dasabuvir tablets), co-packaged for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Merck Co Inc. ZEPATIERTM (Elbasvir and Grazoprevir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Gilead Sciences Inc. Epclusa ® (Sofosbuvir and Velpatasvir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Food and Drug Administration. MAVYRET TM (Glecaprevir and Pibrentasvir) tablets, for oral use. Full prescribing information; 2017 December.
   Google Scholar
• Gilead Sciences Inc. VOSEVI® (Sofosbuvir, Velpatasvir and Voxilaprevir) tablets, for oral use. Full prescribing information; 2017Dec.
   Google Scholar
• Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2014;15:121–130.
   PubMed Web of Science ®Google Scholar
• Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2ʹ-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014;58:3636–3645.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–714.
   PubMed Web of Science ®Google Scholar
• Merck. REBETOL® (ribavirin USP) capsules, for oral use. Full prescribing information; 2017 Dec.
   Google Scholar
• McGivern DR, Masaki T, Williford S, et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology. 2014;147(453–462):e457.
   Google Scholar
• Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011;54:1956–1965.
   PubMed Web of Science ®Google Scholar
• Wang C, Jia L, Huang H, et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother. 2012;56:1588–1590.
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.
   PubMed Web of Science ®Google Scholar
• Wang C, Jia L, O’Boyle DR 2nd, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58:5155–5163.
   PubMed Web of Science ®Google Scholar
• Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22:527–536.
   PubMed Web of Science ®Google Scholar
• Cuenca-Lopez F, Rivero A, Rivero-Juárez A. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2017;13:105–112.
   PubMed Web of Science ®Google Scholar
• Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2017;13:483–490.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Daklinza (daclatasvir): EU summary of product characteristics; 2016 [cited 2017 Dec 21]. Available from: http://www.ema.europa.eu/.
   Google Scholar
• Keating GM. Daclatasvir: a review in chronic hepatitis C. Drugs. 2016;76:1381–1391.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C Virus infection. Drugs. 2015;75:515–524.
   PubMed Web of Science ®Google Scholar
• Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74:1127–1146.
   PubMed Web of Science ®Google Scholar
• Mariño Z, Van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014;63:207–215.
   PubMed Web of Science ®Google Scholar
• Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother. 2014;48:1019–1029.
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677–690.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, De Kanter CT, Van Hoek B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39:589–611.
   PubMed Web of Science ®Google Scholar
• Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Ther Adv Gastroenterol. 2014;7:131–140.
   PubMed Web of Science ®Google Scholar
• Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;19:17–24.
   PubMed Web of Science ®Google Scholar
• Pradat P, Virlogeux V, Gagnieu MC, et al. Ribavirin at the era of novel direct antiviral agents for the treatment of hepatitis C virus infection: relevance of pharmacological monitoring. Adv Hepatol. 2017 Dec 27;2014. Article ID 493087. DOI:10.1155/2014/493087
   Google Scholar
• Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63:832–842.
   PubMed Web of Science ®Google Scholar
• Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 1998;46:563–570.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493–1505.
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 weeks of daclatasvir in combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62:1489–1496.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–1441.
   PubMed Web of Science ®Google Scholar
• Pol S, Bourlière M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66:39–47.
   PubMed Web of Science ®Google Scholar
• Welzel T, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–1870.
   PubMed Web of Science ®Google Scholar
• Petersen J, Welzel T, Herzer K, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European multicentre compassionate use program [abstract no. SAT-184 plus poster]. J Hepatol. 2016;64:S781–2.
   PubMed Web of Science ®Google Scholar
• Herzer K, Welzel TM, Spengler U, et al. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int. 2017;30(3):243–255.
   Google Scholar
• Rockstroh JK, Welzel TM, Ingiliz P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: interim results of a multicenter compassionate use program [abstract no. 1058 plus poster]. Hepatology. 2015;728A–9A.
   Google Scholar
• Weis N, Young J, Hofer H, et al. Effectiveness of daclatasvir based therapy in patients with chronic hepatitis C in Europe: experience from the named patient program [abstract no. SAT-224 plus poster]. J Hepatol. 2016;64:S801.
   Web of Science ®Google Scholar
• Hezode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program [abstract no. 206 plus slide presentation]. Hepatology. 2015;62:314A.
   PubMed Web of Science ®Google Scholar
• Hezode C, Abergel A, Chas J, et al. Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5 and 6 [abstract no. SAT-131 plus poster]. J Hepatol. 2016;64:S755.
   PubMed Web of Science ®Google Scholar
• Leroy V, Hezode C, Metivier S, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicenter compassionate use program [abstract no. SAT-282 plus poster]. J Hepatol. 2016;64:S829.
   Web of Science ®Google Scholar
• Lacombe K, Fontaine H, Dhiver C, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV-HCV coinfection: interim analysis of a French multicenter compassionate use program (AI444-258) [abstract no. TUAB0207LB plus slide presentation]. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancuver, Canada. 2015 July 19-22.
   Google Scholar
• Brown R, Fried M, Reddy RK, et al. Daclatasvir and sofosbuvir therapy for patients with decompensated cirrhosis or post-liver transplant HCV recurrence and advanced fibrosis or cirrhosis: United States multicenter treatment protocol [abstract no. SAT-251 plus poster]. J Hepatol. 2016;64:S814.
   Web of Science ®Google Scholar
• Landis CS, Nelson DR, Sulkowski MS, et al. An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection [abstract no. 716 plus poster]. Hepatology. 2015;62:565A.
   Google Scholar
• Drug interaction daclatasvir, sofosbuvir and ribavirin. Hep drug interaction; 2017 dec 27. Available from: https://www.hep-druginteractions.org/checker
   Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotype 2 and 3. N Engl J Med. 2014;370:1993–2001.
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases and Infectious Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C; [cited 2018 Jul 31]. Available from: http://hcvguidelines.org
   Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263–271.
   PubMed Web of Science ®Google Scholar
• Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062–1068.
   PubMed Web of Science ®Google Scholar
• Alonso S, Riveiro-Barciela M, Fernández I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2017;24:304–311.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Brown RS, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplant. 2016;22:446–458.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Combating hepatitis B and C to reach elimination by 2030. [cited Sept 21th]. Available at Available from: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Viral hepatitis action plan for 2017-2020. [cited Sept 21th]. Available from: https://www.cdc.gov/hepatitis/hhs-actionplan.htm
   Google Scholar
• Cattaneo D, Fossati A, Resnati C, et al. Generics for the treatment of hepatitis C in monoinfected and HIV-coinfected patients: pros and cons. AIDS Rev. 2017;19:167.
   PubMed Web of Science ®Google Scholar
• Premkumar M, Grover GS, Dhiman RK. Chronic hepatitis C: do generics work as well as branded drugs? J Clin Exp Hepatol. 2017;7:253–261.
   PubMed Web of Science ®Google Scholar